HIF2-α Expression in CML Patients Receiving Hydroxyurea Prior to Imatinib That Achieved Major Molecular Response (MMR) versus in Those Not Achieving MMR

References

• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691–709. doi:10.1002/ajh.25792
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2017;28:iv41–iv51. doi:10.1093/annonc/mdx219
   PubMed Web of Science ®Google Scholar
• Cortes J, Quintás-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011;117(6):1113–1122. doi:10.1002/cncr.25527
   PubMed Web of Science ®Google Scholar
• Galinsky I, Buchanan S. Guide to Interpreting disease responses in chronic myeloid leukemia. J Adv Pract Oncol. 2012;3(4):225–236. doi:10.6004/jadpro.2012.3.4.3
   PubMedGoogle Scholar
• Alves R, Gonçalves AC, Rutella S, et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. Cancers. 2021;13(19):4820. doi:10.3390/cancers13194820
   PubMed Web of Science ®Google Scholar
• Antoszewska-Smith J, Pawlowska E, Blasiak J. Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia. Acta Biochim Pol. 2017;64(1):1–10. doi:10.18388/abp.2016_1396
   PubMed Web of Science ®Google Scholar
• Głowacki S, Synowiec E, Szwed M, Toma M, Skorski T, Śliwiński T. Relationship between oxidative stress and imatinib resistance in model chronic myeloid leukemia cells. Biomolecules. 2021;11(4):610. doi:10.3390/biom11040610
   PubMed Web of Science ®Google Scholar
• Kumar H, Choi D-K. Hypoxia inducible factor pathway and physiological adaptation: a cell survival pathway? Mediators Inflamm. 2015;2015:584758. doi:10.1155/2015/584758
   PubMed Web of Science ®Google Scholar
• Gao Q, Ren Z, Jiao S, et al. HIF-3α-induced miR-630 expression promotes cancer hallmarks in cervical cancer cells by forming a positive feedback loop. J Immunol Res. 2022;2022:5262963. doi:10.1155/2022/5262963
   PubMed Web of Science ®Google Scholar
• Jun JC, Rathore A, Younas H, Gilkes D, Polotsky VY. Hypoxia-Inducible Factors and Cancer. Curr Sleep Med Rep. 2017;3(1):1–10. doi:10.1007/s40675-017-0062-7
   PubMedGoogle Scholar
• Loboda A, Jozkowicz A, Dulak J. HIF-1 and HIF-2 transcription factors--similar but not identical. Mol Cells. 2010;29(5):435–442. doi:10.1007/s10059-010-0067-2
   PubMed Web of Science ®Google Scholar
• Deynoux M, Sunter N, Hérault O, Mazurier F. Hypoxia and hypoxia-inducible factors in leukemias. Front Oncol. 2016;6:41. doi:10.3389/fonc.2016.00041
   PubMed Web of Science ®Google Scholar
• Forristal CE, Brown AL, Helwani FM, et al. Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML. Leukemia. 2015;29(10):2075–2085. doi:10.1038/leu.2015.102
   PubMed Web of Science ®Google Scholar
• Chen H, Shen Y, Gong F, Jiang Y, Zhang R. HIF-α promotes chronic myelogenous leukemia cell proliferation by upregulating p21 expression. Cell Biochem Biophys. 2015;72(1):179–183. doi:10.1007/s12013-014-0434-2
   PubMed Web of Science ®Google Scholar
• Rinaldi I, Reksodiputro AH, Jusman SW, et al. Longer hydroxyurea administration prior to imatinib mesylate is risk factor for unsuccessful major molecular response in chronic-phase chronic myeloid leukemia: possibility of P-glycoprotein role. Asian Pac J Cancer Prev APJCP. 2019;20(12):3689–3695. doi:10.31557/APJCP.2019.20.12.3689
   PubMedGoogle Scholar
• Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–757. doi:10.1016/S1470-2045(18)30192-X
   PubMed Web of Science ®Google Scholar
• Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29(6):1336–1343. doi:10.1038/leu.2015.73
   PubMed Web of Science ®Google Scholar
• Höglund M, Sandin F, Hellström K, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122(7):1284–1292. doi:10.1182/blood-2013-04-495598
   PubMed Web of Science ®Google Scholar
• Smith AG, Painter D, Howell DA, et al. Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open. 2014;4(1):e004266. doi:10.1136/bmjopen-2013-004266
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma. 2013;54(7):1411–1417. doi:10.3109/10428194.2012.745525
   PubMed Web of Science ®Google Scholar
• Corm S, Micol J, Leroyer A, et al. Kinetic of chronic myeloid leukaemia (CML) prevalence in Northern France since the introduction of imatinib. J Clin Oncol. 2008;26(15_suppl):7088. doi:10.1200/jco.2008.26.15_suppl.7088
   Web of Science ®Google Scholar
• Au WY, Caguioa PB, Chuah C, et al. Chronic myeloid leukemia in Asia. Int J Hematol. 2009;89(1):14–23. doi:10.1007/s12185-008-0230-0
   PubMed Web of Science ®Google Scholar
• Mendizabal AM, Younes N, Levine PH. Geographic and income variations in age at diagnosis and incidence of chronic myeloid leukemia. Int J Hematol. 2016;103(1):70–78. doi:10.1007/s12185-015-1893-y
   PubMed Web of Science ®Google Scholar
• Qiu G, Xu X, Liu Q. Targeting HIF-2α for the Treatment of CML by affecting LSCs metabolism and the vascular microenvironment. Blood. 2022;140(Supplement 1):5926–5927. doi:10.1182/blood-2022-168304
   Google Scholar
• Ng KP, Manjeri A, Lee KL, et al. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. Blood. 2014;123(21):3316–3326. doi:10.1182/blood-2013-07-511907
   PubMed Web of Science ®Google Scholar
• Litz J, Krystal GW. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther. 2006;5(6):1415–1422. doi:10.1158/1535-7163.MCT-05-0503
   PubMed Web of Science ®Google Scholar
• Gordan JD, Bertovrt JA, Hu CJ, Diehl JA, Simon MC. HIF-2α promotes hypoxic cell proliferation by enhancing c-Myc transcriptional activity. Cancer Cell. 2007;11(4):335–347. doi:10.1016/j.ccr.2007.02.006
   PubMed Web of Science ®Google Scholar
• Rouault-Pierre K, Lopez-Onieva L, Foster K, et al. HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress. Cell Stem Cell. 2013;13(5):549–563. doi:10.1016/j.stem.2013.08.011
   PubMed Web of Science ®Google Scholar